A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
← catalyst calendarNCT06995729 · readout in 358 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
16estimated
Sites
13
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-16 | actual | When the study began enrolling |
| Primary completion | 2027-08-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-12 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acute Treatment of Migraine
Intervention
- Drug: Zavegepant
Primary outcomes
what the primary-completion date above is the date OFMaximum Observed Plasma Concentration (Cmax)
measured Day 1: 0 hour, 1.25 hours, 3.5 hours; Day 2: 18 hours
Time to Reach Maximum Observed Plasma Concentration (Tmax)
measured Day 1: 0 hour, 1.25 hours, 3.5 hours; Day 2: 18 hours
Area Under the Curve From Time Zero to infinity.
measured Day 1: 0 hour, 1.25 hours, 3.5 hours; Day 2: 18 hours
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed